context, we aimed to identify risk factors for in-hospital rebleeding before aneurysm occlusion and focus on the effect of CSF drainage on the incidence of aneurysmal rebleeding.
Methods

Study Population
We conducted a retrospective study of 194 consecutive patients with radiologically confirmed aSAH admitted to the Heinrich-Heine University Medical Centre between May 2012 and January 2016. The ethics committee of Heinrich-Heine University Medical Centre approved this study.
Treatment Protocol
A standardized treatment protocol is applied to all patients admitted to our center with aSAH as described elsewhere. 4, 21 All patients undergo immediate CT angiography and perfusion CT upon admission. Patients are monitored on our neurointensive care unit under a minimal touch regimen until aneurysm closure. The systolic blood pressure (SBP) is lowered so as not to exceed 140 mm Hg. Antifibrinolytic agents are only applied when definite aneurysm closure cannot be achieved within 36 hours.
EVD Management and CSF Drainage
In patients with a Glasgow Coma Scale score below 13, invasive neuromonitoring with insertion of an intraventricular catheter is initiated. All patients adhered to a standardized drainage protocol. The intracranial pressure (ICP) threshold is set at 18 mm Hg. ICP is monitored continuously and CSF is drained in case of sustained elevation of ICP above the set limit. When the ICP exceeded 18 mm Hg for a period longer than 15 minutes, the EVD was opened at a hydraulic pressure level of 18 mm Hg. Drainage of CSF was halted immediately when ICP dropped to 18 mm Hg and none of the patients were treated under a continuous hydraulic drainage paradigm. The drained volume of CSF is documented hourly.
Data Collection and Definitions
For all 194 included patients epidemiological, clinical, and radiological data were collected. From this study population the number of rebleeding events was identified. Aneurysmal rebleeding was defined as CT-confirmed episodes of in-hospital rebleeding in which imaging was prompted by any neurological deterioration, or otherwise clinical suspicious events in comatose patients, such as bradycardia, sudden rise in blood pressure, or the appearance of fresh blood through ventricular drainage. 2 The amount and intensity of blood was compared with that on the preceding CT. Rebleeding before hospitalization was registered; events after aneurysmal obliteration were not included. For further analysis, only patients with CSF drainage initiated at least 6 hours before aneurysm closure were included to allow for uniform analysis of the retrospective data (Fig. 1) . One hundred seventeen patients were excluded from secondary analysis because CSF drainage had been started after aneurysm closure (n = 45), or no CSF drainage was initiated (n = 72). Another 12 patients were excluded because of incomplete data or variable duration of CSF drainage. Therefore, 65 patients (21 men [32.3%], mean age 58.6 ± 12.6 years) were included for further analysis (Fig. 1) . For the included patients we registered the volume of CSF drainage at 6, 12, and 24 hours before aneurysm closure.
Statistical Analysis
Categorical data are presented as counts and percentages and continuous variables as means with standard deviations (SDs) or medians with interquartile ranges (IQRs), depending on the normality of data.
We performed univariate analysis of all clinically important covariates ( sion analysis was performed to ascertain the cutoff point from the variable identified through multivariate analysis for the prediction of rebleeding. For the patients with a volume of CSF drainage above the 50% probability line in the binary logistic regression analysis, we calculated a relative risk with 95% confidence interval (CI) and number needed to harm (NNH) to cause one rebleeding due to high volume CSF drainage. Correlation (R) between individual variables was calculated using Pearson's productmoment correlation. All statistical analysis was performed using the R statistical computing package (version 3.2.2, https://r-project.org/).
Results
Patient Demographics and Rebleeding Incidence
The characteristics of the study population are listed in Table 1 . Pretreatment rebleeding was radiologically confirmed in 26 (13.4%) of 194 patients. These 26 patients had a total of 28 rebleeding events. Ten (5.2%) of these patients suffered a rebleeding event during transport from the referring hospital to our clinic. Two patients had both an out-of-hospital and in-hospital rebleeding event, resulting in a 9.3% (n = 18) in-hospital rebleeding rate. The time distribution of patients with in-hospital rebleeding is depicted in Fig. 2 .
Interventions
The median time to aneurysm repair in all patients was 15 hours (IQR 6-23 hours) after admission; the median time for EVD placement was 3 hours (IQR 2-5 hours). Of the 77 patients who received CSF drainage before aneurysm closure, 17 (22.1%) suffered from aneurysmal rebleeding. Two patients experienced aneurysmal rebleeding shortly after initiation of CSF drainage, and no documented amount of drained CSF volume could be retrieved from the charts. There was no difference in duration of CSF drainage between the rebleeding and nonrebleeding group (17 hours [IQR 7.5-21.5 hours] vs 14 hours [IQR 8.5-21 hours], p = 0.58). In total, 65 patients (33.5%) underwent CSF drainage over the course of at least 6 hours. Characteristics of these patients are listed in Table 2 . Rebleeding occurred in 15 (23.0%) of these patients. In 25 
Risk Factors for Aneurysmal Rebleeding
In multivariate regression analysis the independent predictors for aneurysmal rebleeding were WFNS grade ≥ 4 (p = 0.010) and the initiation of CSF drainage before aneurysm closure (p = 0.001; Table 1 ). Factors related to aneurysmal rebleeding in patients with an EVD before aneurysm closure are presented in Table 2 . The rebleedingpositive group had a significantly higher volume of CSF drainage before aneurysmal rebleeding compared with the rebleeding-negative group ( Fig. 3 ; 63 ml [IQR 55-69 ml] vs 25 ml [IQR 10-35 ml], p < 0.001). In logistic regression analysis, a drained volume of 58 ml within 6 hours was identified as the cutoff value; the lower range of the 95% CI establishes the 50% probability line at 49 ml (Fig.  4) . At 12 hours after EVD insertion the effect remained statistically significant (cutoff value 122 ml, lower 95% CI 98.5 ml; p < 0.001). However, the effect was lost after 24 hours as patients were excluded from further analysis due to aneurysm closure (p = 0.062). The relative risk (RR) for rebleeding after drainage of more than 60 ml in 6 hours is 5.4 times greater compared with patients with less CSF drainage (RR 5.403, 95% CI 2.481-11.767; p < 0.001, NNH 1.687).
Independent predictors for a high volume of CSF drainage were aneurysm diameter (R = 0.301, 95% CI 0.058-0.511, p = 0.016) and WFNS grade (R = 0.263, 95% CI 0.016-0.479, p = 0.038; Table 3 ). We did not find a significant difference in maximal SBP during admission between the rebleeding and the nonrebleeding group (152 ± 24 mm Hg vs 150 ± 20 mm Hg, p = 0.737), nor was there a difference with the maximum SBP within the 30 minutes before aneurysmal rebleeding (126 ± 17 mm Hg vs 150 ± 20 mm Hg). We also did not observe more SBP spikes between the rebleeding and the nonrebleeding groups (above 140 mm Hg, p = 1.000, or 160 mm Hg, p = 0.740). There were no significant differences in international normalized ratio (1.07 ± 0.07 vs 1.04 ± 0.06, p = 0.099), partial thromboplastin time (23.3 ± 3.6 vs 25.9 ± 11.4, p = 0.388), antiplatelet therapy (p = 0.153), or oral anticoagulation (p = 0.381). The absolute thrombocyte count did not differ between the rebleeding (222 ×1000/ μl ± 101) and nonrebleeding groups (226 ×1000/μl ± 56, p = 0.869). Five patients fulfilled the criteria for thrombocytopenia (thrombocyte count below 150 ×1000/μl) and all belonged to the rebleeding group (p < 0.001). When the presence of thrombocytopenia was included in the multivariate analysis it lost significance due to the strong effect of CSF drainage (p = 0.993, Table 2 ).
Discussion
This study revealed some novel issues about management of aSAH before aneurysm closure. First, initiation of external ventricular CSF drainage is independently associated with pretreatment rebleeding. Second, the amount of CSF volume drained is independently correlated with the probability of rebleeding.
Among other factors, such as clinical condition, hypertension, aneurysm size, and amount of subarachnoid blood, the initiation of CSF drainage is an independent risk factor for a rebleeding event after aSAH. 3,5,7,12-14, 19,22 Moreover, its deleterious effect during aneurysmal rerupture suggested CSF drainage should be avoided during recurrent hemorrhages. However, the use of an EVD remains an undisputed and pertinent tool to treat acute hydrocephalus, and continuous CSF drainage has also been advocated in the acute phase after aSAH to reduce the risk of ischemic complications. 11, 17 Despite this controversy, thresholds for the volume of CSF drainage remain undefined even though there have been multiple reports on the adverse effects of early CSF drainage and accidental overdrainage on the incidence of aneurysmal rebleeding within the first 24 hours, highlighting the need for CSF drainage guidelines with defined thresholds. 19, 22 This volume-mediated effect constitutes one of the most important predictors for rebleeding as demonstrated in our cohort. A volume of drained CSF above 60 ml within the first 6 hours significantly increases the rebleeding risk and should be avoided. In this respect, automated ICP-and volume-controlled CSF drainage systems might reduce the risk of rebleeding in these patients. Interestingly, although insertion of an EVD contributes to the rebleeding risk, timing of EVD placement and duration of monitoring and CSF drainage does not (Table 2) .
Both premorbid hypertension and hypertension upon admission are well-known risk factors and are associated with increased severity of the initial bleeding event; these represent significant risk factors for aneurysmal rebleeding. 5, 20 Although hypertension upon and during admission was assessed, we did not include premorbid hypertension in our model. This might have influenced our results because of its significant effect in other reports. In our study, patients with thrombocytopenia are at increased risk of aneurysmal rebleeding. However, this did not improve the validity of risk assessment compared with CSF drainage volume alone. The application of antifibrinolytic drugs prior to EVD placement in patients requiring treatment for acute hydrocephalus should be discussed, as this medication effectively reduces the incidence of rebleeding.
1 However, the benefits of antifibrinolytic agents are still inconclusive due to a significantly higher rate of delayed cerebral ischemia and the failure of these agents to improve overall survival and functional outcome. 1 Its effectiveness in this selected situation therefore remains highly speculative. Recent publications show that aneurysm closure within 24 hours after ictus results in a lower rebleeding rate and improves clinical outcome. 18 However, the median time to aneurysm closure in our population was significantly lower than 24 hours. Aneurysm closure on an emergency basis would be an alternative strategy to reduce rebleeding. 16 Limitations of this preliminary study are those that are generally associated with the retrospective analysis of small patient cohorts. As a result, we were unable to include patients with short periods of CSF drainage, and exact amounts of CSF volume prior to rebleeding could not be determined. We realize that the cutoff of CSF drainage over a 6-hour period is arbitrary, and it was chosen to allow for uniform analysis between patients. Two patients who re-bled were excluded because of this reason and this might have affected our results. Also, because WFNS grade and aneurysm size were independent predictors for a high volume of CSF drainage, it is possible that these factors were driving the rebleeding events, as these parameters have been linked to aneurysmal rebleeding in previous studies. 3, 22 Moreover, our treatment protocol used an intermittent drainage system and is likely to result in greater drops in ICP. As no continuous ICP values were available, we could not determine whether absolute drops in ICP play a role in the etiology of aneurysmal rebleeding. Finally, it is possible that our study underestimates the incidence of early rebleeding. Although the focus of this study does not lie at preadmission rebleeding, patients in poor clinical condition might have had a rebleeding event without clear clinical signs, but it is unlikely that this would go unnoticed under invasive neuromonitoring.
Despite these limitations, we were able to demonstrate a threshold for CSF drainage as one of the paramount contributors to aneurysmal rebleeding and identify a group of patients in great need of a yet undefined treatment protocol. We believe that the risk for early rebleeding can be affected by an adequate treatment strategy, and thus the protocol for a prospective trial to evaluate the role of controlled automated CSF drainage, the use of antifibrinolytic medication, and ultra-early aneurysm closure is currently under development. The beginning of this study is planned for the near future.
Conclusions
The most significant factor of in-hospital rebleeding from an unsecured cerebral aneurysm was initiation of CSF drainage and the volume of drained CSF. This necessitates meticulous control of the amount of drained CSF in patients in whom drainage is needed due to acute hydrocephalus. Development of a definitive treatment protocol for these patients is mandatory.
